Pulmonary dysfunction in Parkinson’s disease: A feature of early disease?
Objective: To characterize the abnormalities in pulmonary function tests (PFT) in early-diagnosed PD patients and to assess their prognostic features 2 years after. Background: Pulmonary…Duloxetine, a serotonin and norepinephrine reuptake inhibitor, reduces daily OFF time in Parkinson’s disease
Objective: To evaluate efficacy of duloxetine on motor symptoms in Parkinson's disease (PD) patients with wearing-off in an open label trial. Background: Duloxetine, a serotonin…Strategies to improve drug development efficiency through regulatory interactions, minimizing the placebo effect and improving data integrity within a phase 3 study of tozadenant in Parkinson’s disease patients with motor fluctuations (TOZ-PD)
Objective: To identify and implement strategies to improve the efficiency of drug development in Phase 3 studies. Background: Conducting global clinical trials can be challenging,…Treating Parkinson’s 2015–A nationwide survey of treatment responses and complications in 1000 Irish patients with Parkinson’s disease
Objective: To collect real-life data from a large cohort with Parkinson's disease (PD), with particular emphasis on drug regimens, motor complications, and quality of life…AntiParkinsonian treatment patterns and motor complications among patients with Parkinson´s disease in Estonia
Objective: To evaluate pharmacological treatment patterns in patients with Parkinson´s disease (PD), prevalence of motor complications, and factors associated with them. Background: Levodopa is the…Objective decrement in Parkinson’s disease – A new parameter for the BRAIN tap test
Objective: To evaluate a new parameter – Bradykinesia Index (BI) as an new objective measure within the BRAIN (BRadykinesia Akinesia INcoordination) tap test. Background: The…Safety, pharmacokinetics, and efficacy of levodopa prodrug ONO-2160/CD: A study in patients with Parkinson’s disease
Objective: The objective of this study was to evaluate the safety, pharmacokinetic profile, and efficacy of ONO-2160/carbidopa (CD) and to compare them with an immediate-release…Validation of an electronic motor diary for patients with Parkinson’s disease
Objective: To determine the reliability and compliance to electronic motor diary in patients with PD. Background: Complexity of motor complications in Parkinson's disease (PD) makes…Pharmacokinetic profile of ONO-2160/CD (levodopa prodrug/carbidopa) in animal and human
Objective: The objective of this study was to characterize pharmacokinetic profile of levodopa prodrug ONO-2160 in animal and human. Background: Motor complications of Parkinson's disease…Construction of a levodopa-response index from wearable sensors for quantifying Parkinson’s disease motor functions: Preliminary results
Objective: The goal of the study is to investigate whether wrist worn motion sensors are feasible tools to measure motor functions in Parkinson's disease (PD).…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.